Literature DB >> 16751162

Intrathecal morphine: effects on perioperative hemodynamics, postoperative analgesia, and stress response for total abdominal hysterectomy.

Semra Karaman1, Seden Kocabas, Meltem Uyar, Ciler Zincircioglu, Vicdan Firat.   

Abstract

Intrathecal opioids provide postoperative analgesia and hemodynamic stability by depressing the neuroendocrine response during the perioperative period. The effects of preoperative intrathecal morphine on perioperative hemodynamics, stress response, and postoperative analgesia were evaluated in patients undergoing abdominal hysterectomy with general anesthesia. A total of 24 patients were randomly assigned to the morphine group (n=12) or the control group (n=12). Patients in the morphine group were given intrathecal 5 microg/kg(-1) morphine before surgery. In all patients, general anesthesia was induced with 1 g/kg(-1) remifentanil, 2 mg/kg(-1) propofol, and 0.1 mg/kg(-1) vecuronium and was maintained with 1% to 2% sevoflurane-35% oxygen in N2O and remifentanil infusion. All patients received intravenous morphine patient-controlled analgesia after surgery. Postoperative pain was evaluated by means of a visual analogue scale. Blood samples were taken at 4 time points before and up to 4 hours after the start of surgery for assessment of plasma epinephrine, norepinephrine, and glucose. Mean arterial pressure (MAP), heart rate (HR), and adverse effects were recorded. Intraoperative hemodynamics was similar in both groups, but postoperative HR and MAP values at 4 h, 8 h, 12 h, and 20 h were significantly lower in the morphine group (P<.05). Postoperative VAS scores, total morphine consumption, and plasma epinephrine, norepinephrine, and glucose levels were significantly lower in the morphine group than in the control group (P<.05). Preoperative intrathecal morphine enhanced the quality of postoperative analgesia, decreased morphine consumption, and depressed the systemic stress response in patients undergoing total abdominal hysterectomy with general anesthesia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751162     DOI: 10.1007/bf02850135

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  6 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Retrospective analysis of high-dose intrathecal morphine for analgesia after pelvic surgery.

Authors:  Annette Rebel; Paul Sloan; Michael Andrykowski
Journal:  Pain Res Manag       Date:  2011 Jan-Feb       Impact factor: 3.037

3.  Effect of Two Different Doses of Dexmedetomidine as Adjuvant in Bupivacaine Induced Subarachnoid Block for Elective Abdominal Hysterectomy Operations: A Prospective, Double-blind, Randomized Controlled Study.

Authors:  Anjan Das; Susanta Halder; Surajit Chattopadhyay; Parthajit Mandal; Subinay Chhaule; Rezina Banu
Journal:  Oman Med J       Date:  2015-07

4.  Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations--Part II.

Authors:  G Nelson; A D Altman; A Nick; L A Meyer; P T Ramirez; C Achtari; J Antrobus; J Huang; M Scott; L Wijk; N Acheson; O Ljungqvist; S C Dowdy
Journal:  Gynecol Oncol       Date:  2016-01-03       Impact factor: 5.482

5.  Comparison of Single-Shot Intrathecal Morphine Injection and Continuous Epidural Bupivacaine for Post-Operative Analgaesia after Elective Abdominal Hysterectomy.

Authors:  Wan Mohd Nazaruddin Wan Hassan; Anafairos Md Nayan; Azmi Abu Hassan; Rhendra Hardy Mohamad Zaini
Journal:  Malays J Med Sci       Date:  2017-12-29

Review 6.  Palliative care in the ICU: relief of pain, dyspnea, and thirst--a report from the IPAL-ICU Advisory Board.

Authors:  Kathleen Puntillo; Judith Eve Nelson; David Weissman; Randall Curtis; Stefanie Weiss; Jennifer Frontera; Michelle Gabriel; Ross Hays; Dana Lustbader; Anne Mosenthal; Colleen Mulkerin; Daniel Ray; Rick Bassett; Renee Boss; Karen Brasel; Margaret Campbell
Journal:  Intensive Care Med       Date:  2013-11-26       Impact factor: 17.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.